271 related articles for article (PubMed ID: 33327291)
1. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
Romero-Gomez M; Kachru N; Zamorano MA; Darba J; Shreay S
Medicine (Baltimore); 2020 Dec; 99(50):e23506. PubMed ID: 33327291
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
[TBL] [Abstract][Full Text] [Related]
3. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients.
C Gordon S; Fraysse J; Li S; Ozbay AB; Wong RJ
Am J Gastroenterol; 2020 Apr; 115(4):562-574. PubMed ID: 31833859
[TBL] [Abstract][Full Text] [Related]
4. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
[TBL] [Abstract][Full Text] [Related]
5. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database.
Boursier J; Shreay S; Fabron C; Torreton E; Fraysse J
EClinicalMedicine; 2020 Aug; 25():100445. PubMed ID: 32775971
[TBL] [Abstract][Full Text] [Related]
6. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases.
Wong RJ; Kachru N; Martinez DJ; Moynihan M; Ozbay AB; Gordon SC
J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):891-902. PubMed ID: 32815873
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany.
Canbay A; Kachru N; Haas JS; Meise D; Ozbay AB; Sowa JP
Ann Transl Med; 2021 Apr; 9(8):615. PubMed ID: 33987313
[TBL] [Abstract][Full Text] [Related]
8. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
Canbay A; Kachru N; Haas JS; Sowa JP; Meise D; Ozbay AB
Aliment Pharmacol Ther; 2020 Oct; 52(7):1185-1194. PubMed ID: 33016540
[TBL] [Abstract][Full Text] [Related]
9. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
[TBL] [Abstract][Full Text] [Related]
10. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
[TBL] [Abstract][Full Text] [Related]
12. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
Estes C; Razavi H; Loomba R; Younossi Z; Sanyal AJ
Hepatology; 2018 Jan; 67(1):123-133. PubMed ID: 28802062
[TBL] [Abstract][Full Text] [Related]
13. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait.
Sanai FM; Al Khathlan A; Al Fadhli A; Jazzar AS; Hashim AM; Mansour E; Abaalkhail F; Hasan F; Al Mudaiheem H; Al Quraishi H; Bottomley J; Alswat KA; Al Ghamdi M; Farghaly M; Fathy M; Awad N; Mohamed O; Kozma S; Al-Hamoudi W; Al-Jedai A
Hepatol Int; 2021 Aug; 15(4):912-921. PubMed ID: 33822317
[TBL] [Abstract][Full Text] [Related]
16. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
[TBL] [Abstract][Full Text] [Related]
18. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study.
Han WM; Apornpong T; Lwin HMS; Thammapiwan S; Boonrungsirisap J; Gatechompol S; Ubolyam S; Tangkijvanich P; Kerr SJ; Avihingsanon A
Clin Infect Dis; 2023 Dec; 77(12):1687-1695. PubMed ID: 37477514
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis.
Tapper EB; Bonafede M; Fishman J; Dodge S; Miller K; Zeng N; Lewandowski D; Bogdanov A
J Med Econ; 2023; 26(1):348-356. PubMed ID: 36866575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]